Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors.

Konen JM, Fradette JJ, Gibbons DL.

Cells. 2019 Dec 24;9(1). pii: E52. doi: 10.3390/cells9010052. Review.

2.

Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.

Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA.

Cancers (Basel). 2019 May 24;11(5). pii: E714. doi: 10.3390/cancers11050714. Review.

3.

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer.

Konen JM, Rodriguez BL, Fradette JJ, Gibson L, Davis D, Minelli R, Peoples MD, Kovacs J, Carugo A, Bristow C, Heffernan T, Gibbons DL.

Cancers (Basel). 2019 Apr 2;11(4). pii: E462. doi: 10.3390/cancers11040462.

4.

Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion.

Richardson AM, Havel LS, Koyen AE, Konen JM, Shupe J, Wiles WG 4th, Martin WD, Grossniklaus HE, Sica G, Gilbert-Ross M, Marcus AI.

Clin Cancer Res. 2018 Jan 15;24(2):420-432. doi: 10.1158/1078-0432.CCR-17-1776. Epub 2017 Dec 5.

Supplemental Content

Loading ...
Support Center